# Treatment of Chronic Itch in Atopic Dermatitis With Opioid Antagonist Naltrexone

> **NCT04325802** · PHASE2 · WITHDRAWN · sponsor: **University of Minnesota**

## Conditions studied

- Atopic Dermatitis
- Pruritus
- Pruritus Chronic
- Dermatitis

## Interventions

- **DRUG:** Naltrexone
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT04325802
- **Lead sponsor:** University of Minnesota
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2022-12-31
- **Primary completion:** 2024-06
- **Final completion:** 2024-06
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Covid-19 pandemic
- **Last updated:** 2023-04-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04325802

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04325802, "Treatment of Chronic Itch in Atopic Dermatitis With Opioid Antagonist Naltrexone". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04325802. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*